HER2-low breast cancer
Oncology · 2023–2024
2decisions
1medicine
2carried consumer input
2individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| trastuzumab deruxtecan Treatment of patients with human epidermal growth factor receptor 2 (HER2) low (immunohistochemical [IHC] 1+ or IHC 2+ and in situ hybridisation [ISH]… | Mar 2024 | Recommended with restriction | input received Breast Cancer Network |
| trastuzumab deruxtecan Treatment of patients with HER2-low (IHC 1+ or IHC 2+/ISH negative) unresectable and/or metastatic breast cancer who have received prior chemotherapy in the… | Nov 2023 | Not recommended | 2 individuals Breast Cancer Network Australia · Breast Cancer Special Interest Group · Rare Cancers Australia · Medical Oncology Group |
Who spoke
Breast Cancer Network · Breast Cancer Network Australia · Breast Cancer Special Interest Group · Rare Cancers Australia · Medical Oncology Group
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.